Drug Saf. 2026 Nov 15. doi: 10.1007/s40264-026-01749-4. Online ahead of print.
ABSTRACT
INTRODUCTION: Additional risk minimisation measure (aRMM) tools should be periodically reassessed to determine whether they remain effective and necessary.
OBJECTIVE: To evaluate discontinuations of aRMM tools for medicinal products in the European Union (EU).
METHODS: We combined a retrospective cohort study with qualitative document analysis of regulatory decisions. Medicinal products centrally authorised with aRMM tools in the EU between July 2012 and December 2021 were included and followed until 31 December 2025. Discontinued aRMM tools were identified through publicly available regulatory documents, and discontinuation rationales were extracted from non-public assessment reports. Kaplan-Meier analyses estimated discontinuation probabilities at product and tool level, and thematic analysis was used to characterise discontinuation rationales.
RESULTS: During follow-up, at least one aRMM tool was discontinued for 22/132 products. The probability of discontinuing at least one aRMM tool within five years after authorisation was 5.0% (95% CI 1.0-8.8; n at risk = 104) and 29.2% (95% CI 16.6-39.9; n at risk = 30) within ten years. 32/306 unique aRMM tools were discontinued, including predominantly educational tools for healthcare professionals (n = 22). The probability of aRMM tool discontinuation within five years after authorisation was 2.5% (95% CI 0.7-4.4; n at risk = 242), increasing to 20.5% (95% CI 13.2-27.1; n at risk = 76) within ten years. Discontinuation decisions were based on multifactorial rationales, related to implementation of aRMM tools, risk-related appropriateness of aRMM tools, and broader regulatory considerations (e.g. consistency across products).
CONCLUSIONS: Post-authorisation discontinuation of aRMM tools occurred in about one-quarter of products within ten years after authorisation. Decisions were multifactorial, with variation in the evidence considered and limited relevance of dedicated effectiveness studies. Clearer guidance, including discontinuation criteria, may improve consistency in decision-making.
PMID:43034970 | DOI:10.1007/s40264-026-01749-4